Greenwich LifeSciences (NASDAQ:GLSI) Raised to “Hold” at Wall Street Zen

Greenwich LifeSciences (NASDAQ:GLSI) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Greenwich LifeSciences in a research report on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $42.00.

Greenwich LifeSciences Stock Performance

Shares of GLSI opened at $20.68 on Friday. The business’s 50-day moving average is $9.87 and its two-hundred day moving average is $10.50. The company has a market capitalization of $286.42 million, a P/E ratio of -14.16 and a beta of 1.61. Greenwich LifeSciences has a fifty-two week low of $7.78 and a fifty-two week high of $22.31.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.30). Analysts forecast that Greenwich LifeSciences will post -0.8 EPS for the current year.

Insiders Place Their Bets

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 10,600 shares of the stock in a transaction on Friday, November 7th. The shares were bought at an average price of $8.43 per share, for a total transaction of $89,358.00. Following the completion of the transaction, the chief executive officer owned 5,583,502 shares of the company’s stock, valued at $47,068,921.86. This trade represents a 0.19% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last ninety days, insiders bought 21,600 shares of company stock valued at $200,900. Corporate insiders own 51.47% of the company’s stock.

Institutional Trading of Greenwich LifeSciences

A number of institutional investors and hedge funds have recently made changes to their positions in GLSI. Bank of America Corp DE increased its position in shares of Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after purchasing an additional 1,322 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Greenwich LifeSciences by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock valued at $1,261,000 after purchasing an additional 1,972 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Greenwich LifeSciences by 15.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 19,007 shares of the company’s stock worth $181,000 after purchasing an additional 2,552 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in Greenwich LifeSciences during the 2nd quarter worth $25,000. Finally, Rhumbline Advisers grew its holdings in shares of Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after buying an additional 3,168 shares in the last quarter. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.